Fusion antigen used as vaccine
The present invention mainly provides a fusion antigen specific for a target cell comprising a ligand moiety which is capable of reacting, recognizing or binding to the receptors on the target cell, a Pseudomonas exotoxin A translocation domain II, an antigenic moiety, and a carboxyl terminal moiety which permits combination of the fusion antigen to the endoplasmic reticulum (ER) membrane of the target cell. A method of immunizing an animal using the fusion antigen is also provided.
1. A fusion antigen specific for a target cell comprising:
an antigenic moiety;
a ligand moiety which is capable of reacting, recognizing or binding to a receptor on the target cell;
a Pseudomonas exotoxin A translocation domain II; and
a carboxyl terminal moiety comprising SEQ ID NO: 10.
2. The fusion antigen according to claim 1 , wherein the target cell is an antigen presenting cell.
3. The fusion antigen according to claim 1 , wherein the target cell is selected from the group consisting of T-cells, B-cells, dendritic cells, monocytes, and macrophages.
4. The fusion antigen according to claim 1 , wherein the antigenic moiety is derived from porcine reproductive and respiratory syndrome virus, Circovirus type II, or human immunodeficiency virus.
5. The fusion antigen according to claim 1 , wherein the antigenic moiety is porcine reproductive and respiratory syndrome virus (PRRSV) ORF 7.
6. The fusion antigen according to claim 1 , wherein the antigenic moiety comprises at least one antigenic unit to which an adjacent antigenic unit is connected by a bridge region.
7. The fusion antigen according to claim 1 , wherein the receptor to be bound to the ligand moiety is selected from the group consisting of antibody receptors, growth factor receptors, lymphokine receptors, cytokine receptors, and hormone receptors.
8. The fusion antigen according to claim 1 , wherein the receptor to be bound to the ligand moiety is selected from the group consisting of TGFα receptors, IL2 receptors, IL4 receptors, IL6 receptors, IGF 1 receptors, CD4 receptors, IL 18 receptors, IL 12 receptors, EGF receptors, LDL receptors and α2-macroglobulin receptors.
9. The fusion antigen according to claim 1 , wherein the ligand moiety is a Pseudomonas exotoxin A binding domain I.
10. A pharmaceutical composition comprising the fusion antigen according to claim 1 together with a pharmaceutically acceptable carrier.
11. A method of inducing an immune response in an animal comprising the steps of:
(a) providing a fusion antigen according to claim 1 ; and
(b) inoculating the fusion antigen into the animal,
wherein the immune response is directed against the pathogen from which the antigenic moiety is derived.
12. The method according to claim 11 , wherein the target cell is an antigen presenting cell.
13. The method according to claim 11 , wherein the antigenic moiety is derived from porcine reproductive and respiratory syndrome virus, Circovirus type II, or human immunodeficiency virus.
14. The method according to claim 11 , wherein the antigenic moiety is porcine reproductive and respiratory syndrome virus (PRRSV) ORF 7.
15. The method according to claim 11 , wherein the antigenic moiety comprises at least one antigenic unit to which an adjacent antigenic unit is connected by a bridge region.
16. The method according to claim 11 , wherein the ligand moiety is a Pseudomonas exotoxin A binding domain I.
17. The method according to claim 11 , wherein the receptor to be bound to the ligand moiety is selected from the group consisting of antibody receptors, growth factor receptors, lymphokine receptors, cytokine receptors, and hormone receptors.
18. The method according to claim 11 , wherein the receptor to be bound to the ligand moiety is selected from the group consisting of TGFα receptors, IL2 receptors, IL4 receptors, IL6 receptors, IGF 1 receptors, CD4 receptors, IL 18 receptors, IL 12 receptors, EGF receptors, LDL receptors and α2-macroglobulin receptors.
19. The method according to claim 11 , wherein the target cell is selected from the group consisting of T cell, B cell, dendritic cell, monocyte, and macrophage.
20. A fusion porcine reproductive and respiratory syndrome virus (PRRSV) ORF 7 antigen comprising
a PRRSV ORF 7 moiety;
a Pseudomonas exotoxin A binding domain I;
a Pseudomonas exotoxin A translocation domain II; and
a carboxyl terminal moiety comprising SEQ ID NO: 10.
21. A pharmaceutical composition comprising the fusion antigen according to claim 20 together with a pharmaceutically acceptable carrier.
22. A method of inducing an immune response in an animal against porcine reproductive and respiratory syndrome virus (PRRSV), which comprises the steps of:
(a) providing a fusion antigen according to claim 20 ; and
(b) inoculating the fusion antigen into the animal.